Kintor Pharmaceutical Limited — Board/Management Information 2021

Apr 30, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [58 x 59] intentionally omitted <==

開拓藥業有限公司 * KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEE

The Board announces that, with effect from 30 April 2021:

• (1) Dr. Bing Chen has resigned as a non-executive Director and a member of the Audit Committee; and

• (2) Dr. Yan Wang has been appointed as a non-executive Director and a member of the Audit Committee.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE AUDIT COMMITTEE

The board (the “ Board ”) of directors (“ Directors ”, each a “ Director ”) of Kintor Pharmaceutical Limited (the “ Company ” and together with its subsidiaries, the “ Group ”) hereby announces that Dr. Bing Chen (“ Dr. Chen ”) has resigned as a non-executive Director and a member of the audit committee of the Company (the “ Audit Committee ”) with effect from 30 April 2021 due to pursuit of his personal commitments.

Dr. Chen has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”).

The Board would like to take this opportunity to express its sincere gratitude to Dr. Chen for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE AUDIT COMMITTEE

The Board further announces that Dr. Yan Wang (王衍) (“ Dr. Wang ”) has been appointed by the Board as a non-executive Director and a member of the Audit Committee with effect from 30 April 2021.

Dr. Wang, aged 32, has joined Highlight Capital (HLC，上海合弘景暉股權投資管理有限公司) since December 2020 as Vice President. He was a senior investment manager at TF Capital (上海 泰甫創業投資管理有限公司) from September 2019 to December 2020. He was a senior manager at WuXi Biologics Co., Ltd. (無錫藥明生物技術股份有限公司) of project management from October 2017 to August 2019. Prior to that, he was a research fellow at Nanyang Technological University of Singapore (新加坡南洋理工大學).

1

Dr. Wang obtained a bachelor’s degree in material chemistry from Peking University in July 2009, and a Ph.D in pharmaceutical sciences from University of Wisconsin-Madison in August 2015. Dr. Wang has entered into a service contract with the Company for an initial term of three years commencing on 30 April 2021, subject to retirement by rotation and re-election at the general meetings of the Company pursuant to the articles of association of the Company. Such service contract may be terminated by not less than one month’s notice in writing served by either party on the other. Dr. Wang will not receive any remuneration for his service as a non-executive Director of the Company.

Save as disclosed above, to the best knowledge and belief of the Board and having made all reasonable enquiries, as at the date of this announcement, Dr. Wang (i) has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years, (ii) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company and (iii) does not have, and is not deemed to have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571) of the Law of Hong Kong.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Dr. Wang as an non-executive Director that need to be brought to the attention of the shareholders of the Company, nor is there any other information that should be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to express its warm welcome to Dr. Wang to the Board.

By order of the Board KINTOR PHARMACEUTICAL LIMITED Dr. Youzhi Tong Executive Director

Hong Kong, 30 April 2021

As at the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Jie Chen, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

• For identification purpose only

2